


# TTFields in combination with immunotherapy

CLINICAL DEVELOPMENT

**Dr. David Tran**  
University of Florida College of Medicine

many patients have  
tumors that appear to  
swell while the patient  
continues to do well

# transient and delayed inflammatory reactions in TTFields responders with GBM





anti-mitotic MOA of  
TTFields based on  
**apoptosis**

TTFields may induce tumor  
inflammation by causing  
immunogenic cell death  
through a **novel mechanism**


potential for far-reaching  
impact on the field of  
cancer immunotherapy

# free DNA formation in the cytoplasm caused by TTFields




free DNA in the cytoplasm  
is highly inflammatory

# critical inflammasomes of innate immunity




# critical inflammasomes of innate immunity



# TTFields successfully produced anti-tumor immunity in animal models of GBM


# immunization plan for animal model studies



combining TTFields with immune checkpoint inhibitors may produce a therapeutic synergy



# 2-THE-TOP phase 2, single arm studying safety and efficacy of TTFields plus pembrolizumab in newly diagnosed GBM



tumor-specific immune activation is currently being investigated with 20 out of 24 patients enrolled to-date